Company profile
Aptevo Therapeutics Inc.
NASDAQ:APVOBiotechnology: Pharmaceutical Preparations
Drug pipeline (3)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| OTLERTUZUMAB | phase1_2 | — | 4 | completed, terminated |
| APVO-414 | phase1 | — | 1 | no active trials |
| Mipletamig | phase1 | — | 2 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (9)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01317901 | phase1 | completed | 2011-05-01 | 2013-04-01 | Aptevo Therapeutics | A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma |
| NCT05934539 | phase1_2 | unknown | 2022-12-23 | 2024-01-01 | Aptevo Therapeutics | ALG.APV-527 First-in-human Study |
| NCT06634394 | phase1 | recruiting | 2024-10-01 | 2027-10-01 | Aptevo Therapeutics | APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML |
| NCT00614042 | phase1 | completed | 2008-01-01 | 2011-12-01 | Aptevo Therapeutics | Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's Lymphoma |
| NCT01644253 | phase1 | terminated | 2012-09-01 | 2020-02-24 | Aptevo Therapeutics | Phase 1b Safety and Efficacy Study of TRU-016 |
FDA applications (0)
No records yet.